Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04018560 · ClinicalTrials.gov registry record · NA
Intensive Referral to Al-Anon: Benefits to Concerned Others and Their Drinkers
A NA study, sponsored by Palo Alto Veterans Institute for Research.
- Completed
- Registry status
- NA
- Development phase
- 402
- Enrollment target
NCT04018560: Completed NA study, sponsored by Palo Alto Veterans Institute for Research.
NCT04018560 is a NA study that has completed, run by Palo Alto Veterans Institute for Research. The registered enrollment target is 402 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04018560, a NA study, has completed, sponsored by Palo Alto Veterans Institute for Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 402 participants
- Enrollment target
Study Summary
This study is examining the effectiveness of Al-Anon Intensive Referral (AIR) with Concerned Others (COs) of individuals in treatment for alcohol use disorders ("drinkers"). AIR's goal is to facilitate Al-Anon participation and positive outcomes among COs.
Primary Outcome
Items are rated on a 5-point scale (0=never, 4=very often). Mental Health is the mean of 10 items (e.g., How often have you experienced feeling hopeful); negative symptoms (e.g., anxious) are reverse scored.
Interventions
- BEHAVIORAL Al-Anon Intensive Referral (AIR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2017-03-07 |
| Est. Completion | 2021-02-28 |
| Phase | NA |
What the finished NCT04018560 record still lists
NCT04018560 is an interventional study that assigns participants to a tested intervention. The registered 402 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 1 intervention - of which Al-Anon Intensive Referral (AIR) is the first listed.
NCT04018560 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04018560 about?
NCT04018560 is a clinical study titled "Intensive Referral to Al-Anon: Benefits to Concerned Others and Their Drinkers". This study is examining the effectiveness of Al-Anon Intensive Referral (AIR) with Concerned Others (COs) of individuals in treatment for alcohol use disorders ("drinkers"). AIR's goal is to facilitate Al-Anon participation and positive outcomes among COs.
What is the current status of trial NCT04018560?
This trial is currently completed. It is a NA study. The enrollment target is 402 participants. The study started on 2017-03-07. Estimated completion is 2021-02-28.
What interventions are being tested in trial NCT04018560?
The interventions under investigation include: Al-Anon Intensive Referral (AIR) (BEHAVIORAL).
Who is sponsoring clinical trial NCT04018560?
This trial is sponsored by Palo Alto Veterans Institute for Research, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04018560's enrollment target sits among peer trials
402 245th of 2000 higher than 1,755 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04464226 · 402 participants · Phase 3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
- NCT05183763 · 402 participants · NA
Medication Adherence Program
- NCT06748222 · 402 participants · Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
- NCT06896474 · 402 participants · NA
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI